Merck Eyes Emerging Biosimilars Market In Japan
This article was originally published in PharmAsia News
Executive Summary
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012
You may also be interested in...
Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin
Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin
Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan